Open AccessHIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana
Author(s) -
Roger Shapiro,
Douglas Kitch,
Anthony Ogwu,
Michael D. Hughes,
Shahin Lockman,
Kathleen M. Powis,
Sajini Souda,
Claire Moffat,
Sikhulile Moyo,
Kenneth McIntosh,
Erik van Widenfelt,
Sheryl Zwerski,
Loeto Mazhani,
Joseph Makhema,
Max Essex
Publication year - 2013
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32836158b0
Subject(s) - nevirapine , medicine , lamivudine , zidovudine , breastfeeding , lopinavir , lopinavir/ritonavir , ritonavir , randomized controlled trial , pregnancy , pediatrics , obstetrics , viral load , surgery , immunology , human immunodeficiency virus (hiv) , viral disease , antiretroviral therapy , virus , biology , hepatitis b virus , genetics
HAART for prevention of mother-to-child HIV transmission (MTCT) may impact long-term survival of women and children.